4.41
+2.32%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Atea Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Atea Pharmaceuticals is based in Boston, Massachusetts and is incorporated in Massachusetts. Its shares trade on Nasdaq under the ticker AVIR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2021, it reported revenue of $351.4m.
We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases. Our current product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which we believe has the potential to improve the current standard of care (“SOC”) for the treatment of patients with hepatitis C virus (“HCV”) infection and AT-587 which we believe has the potential to be the first direct-acting antiviral (“DAA”) for the treatment of patients, particularly immunocompromised patients, with chronic hepatitis E virus (“HEV”) infection.
The objective of our HCV development program is to improve upon the current SOC by offering bemnifosbuvir and ruzasvir as a differentiated pan-genotypic protease inhibitor-free, short-duration regimen for patients infected with HCV, if successfully developed and approved. We believe that a novel treatment regimen that can be easily prescribed will benefit today’s HCV population, which is predominately young (20-49 years old) and non-cirrhotic, and it would be a significant improvement to the current SOC.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Oct 2020
- Employees
- 55
- Website
- ateapharma.com ↗
- Head office
- 225 FRANKLIN STREET, BOSTON, MA, 02110
- Incorporated in
- MA
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Jean-Pierre SommadossiChairman of the Board, President, Chief Executive Officer, Founder, since 2012$4.2m
- Ms. Andrea CorcoranChief Financial Officer, Executive Vice President, Legal, and Secretary$1.9m
- Mr. Wayne FosterExecutive Vice President, Chief Accounting Officer$1.5m
- Dr. Janet HammondChief Development Officer$2.2m
- Dr. Maria HorgaChief Medical Officer$1.9m
- Mr. John VavrickaChief Commercial Officer$1.4m
- Mr. Franklin BergerLead Independent Director$287,564
- Dr. Jerome AdamsIndependent Director$372,022
- Dr. Howard BermanIndependent Director
- Ms. Barbara DuncanIndependent Director$262,022
- Mr. Arthur KirschIndependent Director
- Mr. Bruno LucidiIndependent Director$254,522
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 66
- Social
- 70
- Governance
- 49
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Atea Pharmaceuticals Inc is known for its robust research and development capabilities, which enable the company to develop innovative and effective pharmaceutical products. This strength allows them to stay at the forefront of the industry with cutting-edge solutions.
- The company has an extensive drug pipeline, with multiple potential blockbuster drugs in development. This strong portfolio provides Atea Pharmaceuticals Inc with a competitive advantage and opportunities for future growth.
Weaknesses
- Atea Pharmaceuticals Inc relies heavily on external funding sources to finance its research and development activities. This dependence on external investors or partnerships poses a potential risk if funding sources become limited or unavailable.
- Despite its strengths, Atea Pharmaceuticals Inc has a relatively limited market presence compared to some of its larger competitors. Building a strong brand and expanding market reach may be a challenge for the company.
Opportunities
- The increasing global demand for antiviral drugs presents a significant opportunity for Atea Pharmaceuticals Inc. Their expertise in this field positions them well to capture a larger market share and capitalize on the growing need for effective antiviral therapies.
- Expanding into emerging markets, especially in regions with high incidences of viral infections, could provide Atea Pharmaceuticals Inc with new revenue streams and a larger customer base.
Threats
- The pharmaceutical industry is highly competitive, with numerous well-established players and new entrants constantly emerging. Atea Pharmaceuticals Inc faces the constant threat of competition, which may impact its market share and profitability.
- The pharmaceutical industry is heavily regulated, and Atea Pharmaceuticals Inc must adhere to various regulatory requirements and obtain necessary approvals for its products. Any delays or failures in obtaining approvals can significantly impact the company's operations and financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.